within Pharmacolibrary.Drugs.ATC.N;

model N06AX11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 31.3 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.107,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01583333333333333,
    Tlag           = 9.6
  );

  annotation(Documentation(
    info ="<html><body><p>Mirtazapine is an antidepressant belonging to the class of noradrenergic and specific serotonergic antidepressants (NaSSAs). It is primarily used to treat major depressive disorder and is approved for this indication. It operates by antagonizing central presynaptic α2-adrenergic inhibitory autoreceptors and heteroreceptors, increasing noradrenergic and serotonergic transmission.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of mirtazapine have been reported in healthy adult volunteers, both male and female, after single oral administration.</p><h4>References</h4><ol><li><p>Timmer, CJ, et al., &amp; Delbressine, LP (2000). Clinical pharmacokinetics of mirtazapine. <i>Clinical pharmacokinetics</i> 38(6) 461–474. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200038060-00001&quot;>10.2165/00003088-200038060-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10885584/&quot;>https://pubmed.ncbi.nlm.nih.gov/10885584</a></p></li><li><p>Puzantian, T (1998). Mirtazapine, an antidepressant. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 55(1) 44–49. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/55.1.44&quot;>10.1093/ajhp/55.1.44</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9437474/&quot;>https://pubmed.ncbi.nlm.nih.gov/9437474</a></p></li><li><p>Rouini, MR, et al., &amp; Giorgi, M (2014). Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates. <i>Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences</i> 22(1) 13–None. DOI:<a href=&quot;https://doi.org/10.1186/2008-2231-22-13&quot;>10.1186/2008-2231-22-13</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24397986/&quot;>https://pubmed.ncbi.nlm.nih.gov/24397986</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AX11;
